Key facts
- This page summarizes Scott Thomas Smith's Form 4 filing for Ascendis Pharma A/S (ASND).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Jun 2026, 16:25.
Scott Thomas Smith - 02 Jun 2026 Form 4 Insider Report for Ascendis Pharma A/S (ASND)
- Reporting relationship
- EVP & Chief Financial Officer
- Issuer ticker
- ASND
- Reported as of
- 02 Jun 2026
- Net transaction value
- +$21,900
- SEC form
- 4
- Accepted by SEC
- 02 Jun 2026, 16:25:15 UTC
- Prior SEC filing
- 01 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Wolff Jensen as attorney-in-fact for Scott Smith
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Scott Thomas Smith filed Form 4 for Ascendis Pharma A/S (ASND) on 02 Jun 2026.
Change
- Previous filing in this sequence was filed on 01 Jun 2026.
- Current net transaction value: +$21,900.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001965550
Primary reporting owner
SMITH SCOTT THOMAS
- Relationship
- EVP & Chief Financial Officer
- Address
- C/O ASCENDIS PHARMA A/S, TUBORG BOULEVARD 12, HELLERUP, DENMARK
- Signature
- /s/ Michael Wolff Jensen as attorney-in-fact for Scott Smith
- Signature date
- 02 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ASND
transaction
Ordinary Shares
Purchase
- Transaction value
- $21,900
- Shares
- +100
- Change %
- +2.3%
- Price
- $219.00
- Shares after
- 4,367
- Date
- 02 Jun 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.